资金加速流入科技与生物医药，港股未来还有哪些机会？

Group 1 - The Hong Kong stock market has seen a significant recovery this year, with IPO financing reaching HKD 182.9 billion by the end of September, more than doubling compared to the same period in 2024 [1] - Nearly half of the companies applying for listing are from the technology sector, focusing on areas such as artificial intelligence, semiconductors, and robotics, along with a notable presence of biopharmaceutical companies [1][2] - The Hang Seng Technology Index has increased by 32.56% as of October 22, while the Hang Seng Biotech ETF has surged by 80.08% [1] Group 2 - The structure of listed companies on the Hong Kong Stock Exchange is shifting from finance and real estate to technology, aligning with China's economic transformation and regulatory innovations [2] - The most voted sectors for investment value in the next 1-2 years include internet and artificial intelligence, biopharmaceuticals, and semiconductors [2] - The technology manufacturing sector is identified as a crucial area for China, encompassing AI hardware, semiconductors, new energy, and robotics [2] Group 3 - The Hong Kong Stock Exchange is set to launch Hang Seng Biotech Index futures, providing diversified and professional risk management tools for investors [3] - Attracting high-quality global companies to list in Hong Kong is essential for enhancing the market's appeal to quality investors and improving the range of investment tools available [3] - There is an expectation for Hong Kong to expand its market connectivity, potentially enhancing its status as an international financial center by linking with other major global financial markets [3]